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Abstract
Background: HIV-1 infection impairs tuberculosis (TB) specific immune responses affecting the diagnosis of latent
TB. We aimed to (1) determine the proportion of HIV-1-infected adults with a negative QuantiFERON®-TB Gold
in-tube (QFT-GIT) and Tuberculin skin testing (TST) that convert to QFT-GIT positive following TST, and (2) evaluate
the relationship between conversion and baseline QFT-GIT results.
Methods: HIV-1 infected adults being screened for a TB vaccine study in South Africa underwent QFT-GIT followed
by TST. As per protocol, QFT-GIT was repeated if randomization was delayed allowing for evaluation of TST
boosting in a proportion of participants.
Results: Of the 22 HIV-1 infected, TST and QFT-GIT negative adults (median CD4 477/mm3 IQR 439–621) who had
QFT-GIT repeated after median 62 days (IQR 49–70), 40.9 % (95 % CI 18.6–63.2 %) converted. Converters had a
significantly greater increase in the background subtracted TB antigen response (TBAg-Nil – all units IU/mL)
following TST, 0.82 (IQR 0.39–1.28) vs 0.03 (IQR −0.05–0.06), p = 0.0001. Those who converted also had a significantly
higher baseline TBAg-Nil 0.21(IQR 0.17–0.26) vs 0.02(IQR 0.01–0.07), p = 0.002. Converters did not differ with regard
to CD4 count or ART status. ROC analysis showed a baseline cut off of 0.15 correctly classified 86.4 % of converters
with 88.9 % sensitivity.
Conclusions: Our findings support the possibility that there are 2 distinct groups in an HIV-1 infected population
with negative QFT-GIT and TST; a true negative group and a group showing evidence of a weak Mtb specific
immune response that boosts significantly following TST resulting in conversion of the test result that may
represent false negatives. Further evaluation of whether a lower cut off may improve sensitivity of QFT-GIT in this
population is warranted.
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Background
The diagnosis of latent tuberculosis (TB) relies on the
demonstration of an acquired cell-mediated immune
response to Mycobacterium tuberculosis (Mtb) in an
otherwise asymptomatic person, either by Tuberculin skin
testing (TST) or Interferon gamma release assays (IGRA)
(e.g., QuantiFERON®-TB Gold in-tube (QFT-GIT) and T-
SPOT.TB) [1].
HIV-1 infection results in the depletion of Mtb specific
CD4 cells [2] and impaired effector responses to Mtb
antigens, which could result in a false negative test for
latent TB. For TST, where diameter of skin induration is
measured, a lower cut-off of 5 mm rather than 10 mm is
therefore commonly used to improve sensitivity [3].
Alternatively a 2-stage testing approach, where the TST
is repeated 1–4 weeks after an initial negative test, im-
proves sensitivity. The initial TST is thought to boost a
* Correspondence: hanif.esmail@ndcls.ox.ac.uk
Katalin A. Wilkinson and Robert J. Wilkinson are joint senior authors.
†Equal contributors
1Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases
and Molecular Medicine, University of Cape Town, Cape Town, South Africa
2Department of Medicine, Imperial College London, London, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Esmail et al. BMC Infectious Diseases  (2016) 16:545 
DOI 10.1186/s12879-016-1875-6
weak pre-existing antigen specific response, resulting in
a positive test when repeated [4].
Unlike TST, IGRAs have adopted a single cut-off
(QFT-GIT TBAg-Nil > 0.35 IU/mL, T-SPOT.TB > 5 spots)
regardless of HIV-1 status. HIV-1 co-infection however
has been shown to result in a reduced sensitivity of both
IGRA platforms for tuberculosis [5, 6]. Boosting of inter-
feron gamma release from circulating blood cells following
TST has been observed within 3 days of administration
[7]. This can result in conversion of IGRA from negative
to positive, but occurs in less than 5 % of TST negative/
IGRA negative cases in HIV-uninfected populations
[8–11]. The impact of TST on IGRA conversion in
immunocompromised persons such as those with
HIV-1 infection has not been assessed.
In this study we evaluated the impact of TST on QFT-
GIT conversion in HIV-1-infected persons that were
initially TST and QFT-GIT negative and hence con-
sidered as not having evidence of latent infection. We
then aimed to evaluate differences in baseline QFT-
GIT response between those that converted and those
that did not.
Methods
Study population
The study was conducted, in Khayelitsha, Cape Town,
within the screening period of a TB vaccine trial, which
enrolled participants between August 2011 and April
2013 [12]. The study adhered to International Confer-
ence on Harmonisation Good Clinical Practice guide-
lines, and was approved by the University of Cape
Town’s Faculty of Health Sciences Human Research
Ethics Committee. All participants provided written in-
formed consent. Healthy HIV-1-infected adults with
baseline CD4 counts above 350/mm3, if not receiving
antiretroviral therapy (ART), or above 300/mm3 with
suppressed HIV viral load, if receiving ART, were eligible
for the vaccine trial. As part of the screening process all
participants were assessed for active TB by symptom
screen, chest radiograph (CXR) and sputum culture and
for latent TB by QFT-GIT followed by TST. Those with
no evidence of active or latent TB were eligible for
randomization into the vaccine trial. However, if >
45 days had elapsed since screening initiation, the proto-
col determined that participants should be rescreened
prior to randomization. This included repeating the
QFT-GIT. In March 2012 there was a brief sponsor initi-
ated suspension in recruitment to the vaccine trial. As a
result when recruitment was reinitiated in April 2012 a
number of screened participants breeched the 45-day
rule and required rescreening. This pause in recruitment
allowed assessment of boosting of the response following
the initial TST presented here. The study was observa-
tional and did not have a control arm.
Tuberculin skin testing and QFT-GIT
TST was administered as an intradermal injection of
2TU (0.1ML) of PPD-RT23 (Statens Serum Institut,
Copenhagen, Denmark) into the volar aspect of the
forearm and performed immediately after blood had
been drawn for baseline QFT-GIT. Maximal transverse
induration was measured at 48–72 h by clinical research
nurses trained to do so. Induration < 5 mm was consid-
ered negative.
The QFT-GIT assay (Qiagen, Valencia, CA) was per-
formed in accordance with manufacturer’s instructions.
The following measures were implemented in order to
minimise variation in assay results: (1) All samples were
taken by research nurses trained and assessed to ensure
consistent sampling methodology. (2) Following blood
draw samples were kept in temperature-logged insulated
transport boxes and samples were incubated within 4 h
of blood draw. (3) Incubation time was standardized to
24 h. (4) QFT-GIT assay was performed by Good
Laboratory Practice (GLP) trained research technicians
in a Foundation of Innovative New Diagnostics (FIND)
accredited laboratory with regular sponsor mandated
Quality Assurance (QA) undertaken to ensure reprodu-
cibility of results.
Statistical methods
Statistical analysis was conducted in Stata ver. 12.1
(StataCorp). Gaussian distribution of data was determined
by the Shapiro-Wilk test. Non-parametric independent
data was compared using Mann-Whitney U test and para-
metric data compared using t-test. Non-parametric paired
data was compared by Wilcoxon signed-rank Proportions
were compared by χ2 test or Fisher’s exact test (if the
contingency included a number ≤ 5). Receiver Operating
Characteristic (ROC) analysis was performed as a non-
parametric test.
Results
Twenty-two HIV-1-infected adults screened for the vac-
cine trial with a negative TST and QFT-GIT required
rescreening (due to brief suspension in recruitment) and
therefore had a repeat QFT-GIT performed at a median
of 62 days (IQR 49–70) after the TST. The TST was
0 mm in all participants. 90.9 % of participants were fe-
male and all were resident in Khayelitsha, a peri-urban
township of Cape Town. Median age was 33 years (IQR
29–40). 16 participants (73 %) were on ART for a me-
dian of 2.0 years (IQR 1.5–3.5) and had a suppressed VL
(either lower that detectable limit (LDL) or <40 copies/
mL). Seven participants (31.8 %) had been treated for ac-
tive TB a median of 3.7 years previously (IQR 2.0–4.2).
Median VL for those not on ART was 17,309 copies/ml
(IQR 10,563–34,735). Median CD4 count for the 22 par-
ticipants was 477/mm3 (IQR 439–621). All participants
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had negative sputum culture and a CXR without evi-
dence of active TB.
Nine of 22 participants (40.9 %, 95 % CI 18.6–63.2 %)
demonstrated conversion from negative (<0.35 IU/ml) to
positive QFT-GIT during the interval between tests.
There was no significant difference in CD4 count, age,
sex, proportion on ART, previous TB treatment or time
between initial and repeat IGRA between those that
converted and those that did not (Table 1). However, in
those who converted, the median baseline TBAg-Nil of
0.21 IU/ml (IQR 0.17–0.26) was significantly higher
compared to non-converters (0.02 IU/ml, IQR 0.01–0.07,
p = 0.002) as was the change in TBAg-Nil post TST,
0.82 IU/ml (IQR 0.39–1.28) compared to 0.03 IU./ml
(IQR −0.05–0.06, p = 0.0001), respectively. The repeat
TBAg-Nil, post TST, was significantly higher in converters
(0.84 IU/ml (IQR 0.65–1.50), p = 0.008) but not in non-
converters 0.06 IU/ml (IQR 0.00–0.10), p = 0.86 (Fig. 1).
In order to determine if a specific cut-off could effect-
ively identify converters, ROC analysis was performed
on the baseline TBAg-Nil values. Area under the curve
(AUC) of baseline TBAg-Nil to identify converters was
0.87 (95 % CI 0.69–1.00). TBAg-Nil cut-off values of
0.15 IU/ml and 0.17 IU/ml both correctly classified
86.4 % of converters, with 0.15 IU/ml cut-off having a
higher sensitivity (88.9 % vs 77.8 %) and 0.17 IU/ml hav-
ing a higher specificity (92.3 % vs 84.6 %) (Fig. 2).
Discussion
We have shown that in an HIV-1-infected population
living in high TB burden setting, over 40 % of those with
an initially negative QFT-GIT (TBAg-Nil <0.35 IU/ml)
and TST (<5 mm) convert to QFT-GIT positive (TBAg-
Nil ≥0.35 IU/ml) within 7–10 weeks of a TST. We have
also demonstrated that converters have a higher baseline
QFT-GIT TBAg-Nil and that a baseline cut-off value of
0.15 IU/ml correctly classifies 86.4 % of converters with
88.9 % sensitivity. This rate of conversion is considerably
higher than in previous studies conducted in a variety of
settings with low HIV prevalence [8–11].
Although our study was conducted in a setting of high
TB incidence it is unlikely that the 40 % conversion rate
represents acquired infection over a 7–10 week period.
The estimated force of infection in this setting is less
than 8 % per year, therefore the expected rate of new in-
fection over a 7–10 week period would be less than
1.5 % [13]. Furthermore if acquired infection was re-
sponsible for conversion, this would not be expected to
relate to baseline QFN-GIT response.
Converters in our study had a significantly higher
baseline TBAg-Nil than non-converters (0.21 vs 0.02). In
addition to this, following TST, converters also had a
significantly greater increase in TBAg-Nil with non-
converters generally showing minimal change post TST
(0.82 vs 0.03) demonstrating that TST did not just simply
result in a uniform boosting in IFNγ production in all par-
ticipants. The low baseline response and minimal boosting
in non-converters in our study are similar to the responses
in HIV-uninfected participants that are TST and QFT-
GIT negative (<0.35 IU/mL) at baseline. Sauzullo et al.
found 69 TST negative Italian healthcare workers to have
QFT-GIT TBAg-Nil <0.03 IU/ml and <0.08 IU/ml before
and 6 weeks after TST, respectively [8]. By contrast, previ-
ous studies have demonstrated that persons with positive
QFT-GIT (>0.35 IU/mL) at baseline are more likely to
show an increase in TBAg-Nil following TST than those
with a negative QFT-GIT [14].
Taken together, our data supports the possibility that
within this population of HIV-1-infected persons with
negative TST and QFT-GIT there may be 2 distinct pop-
ulations. A true negative group that have no evidence of
immune sensitization by Mtb even following stimulation
with mycobacterial peptides in the form of PPD and a
false negative group that show initial evidence of weak
antigen specific immune response to Mtb, as determined
by IFNγ release in whole blood stimulated by ESAT-6,
Table 1 Table showing differences in characteristics between converters and non-converters
Variable Overall population
n = 22
Converters
n = 9
Non-converters
n = 13
p-value
Age (years) – Med(IQR) 33(29–40) 32(29–40) 36 (30–39) 0.52
Sex - Female 90.9 % 100 % 84.6 % 0.49
CD4 count (/mm3) – Med(IQR) 477 (439 – 621) 466 (426–720) 477 (458–589) 0.87
On ART 73 % 66.6 % 76.9 % 0.66
Previous TB treatment 31.8 % 23.1 % 44.4 % 0.37
Time between tests (days) – Med(IQR) 62 (49–70) 50 (46–62) 69 (58–71) 0.11
Baseline TBAg-Nil (IU/ml) – Med (IQR) 0.07 (0.01–0.21) 0.21 (0.17–0.26) 0.02 (0.01–0.07) 0.002
Change in TBAg-Nil (IU/ml) – Med(IQR) 0.09 (−0.05–0.62) 0.82 (0.39–1.28) 0.03 (−0.05–0.06) 0.0001
Characteristics of 9 converters and 13 non-converters compared. Gaussian distribution of data determined by Shapiro-Wilk test. Non-parametric data compared
using Mann-Whitney U test and parametric data compared using t-test. Proportions were compared by χ2 test or Fisher’s exact test (if the contingency included
a number ≤ 5)
Med Median, IQR Interquartile range, ART Antiretroviral therapy, IU international units
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CFP-10, and TB7.7, that can be boosted by intra-dermal
PPD injection. One explanation for this phenomenon is
that pre-existing memory responses may be stimulated
by PPD (which include antigens ESAT-6 and CFP-10)
when TST is performed [15]. This may lead to prolifera-
tion of antigen specific effector cells which may then be
present in greater numbers when peripheral blood is
restimulated ex vivo when the repeat QFT-GIT is per-
formed resulting in greater IFNγ release, and a positive
QFT-GIT. Our data also suggest that a lower cut-off
may improve sensitivity of QFT-GIT for the detection of
latent TB in HIV-1-infected persons. Intuitively, having
a lower cut-off in HIV-1-infected persons for an
immune-diagnostic test is logical as the cells which con-
tribute to a positive result are especially susceptible to
HIV-1 induced depletion [2].
A limitation of the study was that we were unable to
validate a lower cut-off for QFT-GIT in HIV-1-infected
persons. It would also be important to ensure that any
novel cut-off for HIV-1-infected persons was validated
for a range of CD4 counts. Furthermore our study was
only conducted using QFT-GIT, it would be of interest
to determine if a similar phenomenon occurred using
the TSPOT.TB assay. It was beyond the scope of the
study to investigate whether participants that converted
had any immunological differences in phenotype or
function of antigen specific T cells in comparison to
non-converters. In particular it would be of interest to
investigate if converters had evidence of antigen specific
central memory responses not present in non-converters
as this would have supported the assertion that they rep-
resented distinct subgroups.
Conclusion
We have demonstrated that in an HIV-1 infected popu-
lation with negative QFT-GIT and TST (that would con-
ventionally be characterised as not having latent TB
infection and not considered for IPT) there are 2 distinct
groups. One group shows evidence of a weak Mtb spe-
cific immune response that boosts significantly following
TST resulting in conversion of the test result and may
represent a false negative group that may benefit from
IPT. We propose that a lower cut off, between 0.15 and
0.17, may improve sensitivity of QFT-GIT and warrants
further validation.
Cut-point Sensitivity Specificity Correctly LR+ LR-
classified
-0.08 100.0% 0.0% 40.9% 1.0 –
0 100.0% 7.7% 45.5% 1.1 0.0
0.01 100.0% 23.1% 54.6% 1.3 0.0
0.02 100.0% 46.2% 68.2% 1.9 0.0
0.05 88.9% 53.9% 68.2% 1.9 0.2
0.07 88.9% 61.5% 72.7% 2.3 0.2
0.15 88.9% 84.6% 86.4% 5.8 0.1
0.16 77.8% 84.6% 81.8% 5.1 0.3
0.17 77.8% 92.3% 86.4% 10.1 0.2
0.2 66.7% 92.3% 81.8% 8.7 0.4
0.21 55.6% 92.3% 77.3% 7.2 0.5
0.22 44.4% 92.3% 72.7% 5.8 0.6
0.26 33.3% 92.3% 68.2% 4.3 0.7
0.29 22.2% 92.3% 63.6% 2.9 0.8
0.31 11.1% 92.3% 59.1% 1.4 1.0
0.33 0.0% 92.3% 54.6% 0.0 1.1
0.33 0.0% 100.0% 59.1% – 1.0
a
b
Fig. 2 ROC analysis. a. Figure showing ROC analysis for baseline
TBAg-Nil to distinguish converters and non-converters. b Table
showing sensitivity, specificity, proportion correctly classified, positive
likelihood ratio and negative likelihood ratio for each cut-off value.
LR + = positive likelihood ratio, LR- = negative likelihood ratio
a
Fig. 1 Change in QFT-GIT TBAg-Nil before and after TST. Graph showing
TBAg-Nil level for participants at baseline and after boosting. Values for
individual participants connected with line. Values <0 IU/mL not shown
on graph
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